Date: September 14, 2022          Administrative Circular: 2022:37

ATTN: Medical Health Officers and Branch Offices
     Public Health Nursing Administrators and Assistant Administrators
     Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
   Part 4 – Biological Products

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine Eligibility

Footnote B was revised to remove pregnant persons from those who may receive a booster
dose 8 weeks after completion of the primary series.

Please remove page numbers: 1-3 dated September 8, 2022
Please add new page numbers: 1-3 dated September 14, 2022

The following COVID-19 vaccine product pages have been updated to indicate the
following:

- Doses and Schedule:
  - Content has been revised to indicate that the minimum interval between
    completion of the primary series and the booster dose is 3 months. This
    revised minimum interval additionally applies to pregnant people and aligns
    with the National Advisory Committee on Immunization’s Updated guidance on
    COVID-19 vaccines for individuals who are pregnant or breastfeeding. The
    exception to this is the Janssen vaccine for which the minimum interval is 8
    weeks between the single dose of Janssen vaccine and the booster dose.

COVID-19 Vaccine Comirnaty® (Pfizer-BioNTech) Adult/Adolescent (Gray Vial Cap)

In addition to the revision to the Doses and Schedule indicated above the Product
Components have been corrected to include tromethamine and tromethamine hydrochloride.

Please remove page numbers: 1-5 dated September 8, 2022
Please add new page numbers: 1-5 dated September 14, 2022
The following COVID-19 vaccine product pages have been updated to indicate the following:

- **Booster Doses:**
  - Content has been revised to indicate that the minimum interval between completion of the primary series and the booster dose is 3 months. This revised minimum interval additionally applies to pregnant people and aligns with the National Advisory Committee on Immunization’s [Updated guidance on COVID-19 vaccines for individuals who are pregnant or breastfeeding](https://www.canada.ca/en/public-health/services/publications/vaccination-safety-data/updated-guidance-covid-19-vaccines-who-pregnant-breastfeeding-clinicians-professionals.html).

**COVID-19 Vaccine Comirnaty® (Pfizer-BioNTech) Adult/Adolescent (Purple Vial Cap)**

Please remove page numbers: 1-5 dated September 8, 2022
Please add new page numbers: 1-5 dated September 14, 2022

**COVID-19 Vaccine SPIKEVAX™ (Moderna) 6 Years of Age and Older (Red Vial Cap)**

Please remove page numbers: 1-5 dated September 8, 2022
Please add new page numbers: 1-5 dated September 14, 2022

**COVID-19 mRNA Vaccine Spikevax™ Bivalent (Moderna)**

Please remove page numbers: 1-4 dated September 8, 2022
Please add new page numbers: 1-4 dated September 14, 2022

**COVID-19 Vaccine VAXZEVRIA™ (AstraZeneca)**

Please remove page numbers: 1-4 dated September 8, 2022
Please add new page numbers: 1-4 dated September 14, 2022

**COVID-19 Vaccine NUVAXOVID™ (Novavax)**

Please remove page numbers: 1-3 dated September 8, 2022
Please add new page numbers: 1-3 dated September 14, 2022
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

cc:
    Provincial Health Officer
    Dr. Bonnie Henry

    BC Ministry of Health,
    Population & Public Health Division:

    Brian Sagar
    Senior Director Communicable Disease,
    Population and Public Health Division

    Bernard Achampong
    Executive Director,
    Public Health, Planning and Prevention,
    Population and Public Health Division